Months after lowering its full-year guidance, Iovance Biotherapeutics has slashed its headcount by fewer than 20%, according to an Aug. 6 report from Endpoints News, which confirmed the layoffs with a company spokesperson. “This restructuring will extend our cash runway,” the spokesperson told Endpoints, adding that the layoffs will “support [its] mission to innovate, develop and deliver” its pipeline of tumor-infiltrating lymphocyte cell therapies for patients who need them.
